Table 6 Association of statin use with mortality in patients with cardiovascular disorders.

From: The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis

Characteristic

Statin Use (Intention-to-treat)

Statin Use (Per-protocol)

Unadjusted HR

(95%CI)

P-value

Adjusted HR#

95%CI

P-value

Unadjusted HR

(95%CI)

P-value

Adjusted HR#

95%CI

P-value

All-cause mortality

0.51

0.28–0.90

0.021

0.41

0.19–0.84

0.015

0.46

0.23–0.95

0.036

0.41

0.18–0.96

0.041

Infection-related mortality

0.55

0.26–1.16

0.116

0.42

0.17–1.06

0.065

0.55

0.26–1.16

0.116

0.43

0.15–1.25

0.122

  1. #Adjusted for age, gender, body mass index (BMI), diabetes mellitus (DM), hypertension (HTN), cancer, chronic kidney disease (stage 3–5), asthma, chronic obstructive pulmonary disease (COPD), liver cirrhosis, transplant status, baseline sputum AFB status, cavitary disease at baseline, metformin use, and calcium channel blocker use.
Back to article page